Jason Carroll

Cofounder, Hudson River Trading

Search every verified Jason Carroll interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Jason Carroll, CEO and Executive Director of Entropy Neurodynamics, discussed the company's progress in psychedelic drug delivery during a May 2026 interview. He described the company's approach as delivering a precise IV infusion of psilocin, the active ingredient in psilocybin, which he said offers more control and less variability compared to oral psilocybin. Carroll highlighted recent clinical results for the compound TRP 803 in treating irritable bowel syndrome, presented at a major gastroenterology conference by researchers from Massachusetts General Hospital and Columbia University. He stated the results showed a 75% responder rate in a treatment-resistant group, which he described as the strongest result of any IBS therapy. Carroll outlined upcoming milestones, including data from a binge eating disorder study expected in July and a second cohort in the fourth quarter of 2026. He also said the company is close to announcing a parallel study involving over 60 patients across multiple indications, which he described as the most significant study of its kind in psychiatry. He noted that the company's primary focus remains psychiatry, but the IBS results provide a potential parallel approval pathway through gastroenterology.